{ "id": 4444, "date": "2022-05-02T14:26:08", "date_gmt": "2022-05-02T05:26:08", "guid": { "rendered": "https:\/\/miraieye.ekrasunya.com\/?page_id=4444" }, "modified": "2024-08-26T10:51:49", "modified_gmt": "2024-08-26T01:51:49", "slug": "company-overview-01", "status": "publish", "type": "page", "link": "https:\/\/miraieye.co.jp\/en\/", "title": { "rendered": "Company Overview" }, "content": { "rendered": "
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

Company Overview<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

\u25a0 Corporate Philosophy<\/a><\/h4>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t

\u25a0 Greetings from the President<\/a><\/h4>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t

\u25a0 Company Profile<\/a><\/h4>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t

\u25a0 Company History<\/a><\/h4>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t

\u25a0 R&D Promotion and Commercialization System<\/a><\/h4>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

\u25a0 Corporate Philosophy<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t

Future Vision for Future Life<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

We support the passions of individuals who are always striving forward despite encountering failures.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

We foster better pricing by promoting new and original ideas.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

We provide better vision – MIRAI EYE (Future Vision)- through our innovative technologies
to people all over the world suffering from presbyopia and\/or cataracts.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\tWe also contribute to the fulfilment of living a better life as we age.<\/span>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

We focus on improving our immediate world which surrounds us daily; for the ultimate goal of achieving a better life for people across the world.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

\u25a0 Greetings from the President<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

After the age of 40, almost all people tend to have presbyopia<\/strong>. After the age of 60, almost all people develop cataract<\/strong>. In the present scenario characterized by the global trend of an ageing population, surgical correction of presbyopia and cataract<\/strong> is a strong demand of the era.<\/p>

We will develop a new type of Intraocular Lens (IOL) that can resolve both presbyopia and cataract<\/strong>\u00a0at the same time. This has not yet been created successfully before. Our development of IOLs with accommodative function started back in 2010 by Frontier Vision Inc.<\/strong>, our sister company which develops and distributes cataract surgery simulators. In 2014, the R&D of the Accommodating IOL (A-IOL) was adopted as an A-STEP program of the Japan Agency for Medical Research and Development (AMED)<\/strong>.<\/p>

In 2017, Mirai Eye Inc.<\/strong> was founded to transfer the IOL-related development from Frontier Vision Inc. and the development of the A-IOL was adopted as an ACT-MS Program of AMED<\/strong>. Since then, Mirai Eye Inc. has developed two IOLs which are the \u201cSimple-Move Lens (SML)\u201d<\/strong> and \u201cActive-Move Lens (AML)\u201d<\/strong>. This has been in collaboration with Meiho Co. Ltd. (Japan), Excel Optics Pvt. Ltd. (India) and Sankara Eye Hospital (India).<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

President & CEO<\/strong>
Junsuke Akura<\/strong><\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

The AML<\/strong> is an A-IOL that induces a large accommodation power by changing the curvature of a lens optic, which contributes to humanity\u2019s visual future. The target population for this IOL is roughly two billion people who are affected by presbyopia, and it creates a massive new market for correcting presbyopia. The prototype of this lens has already been developed, and its efficacy and safety will be evaluated via in-vitro and animal studies. <\/span><\/p>

The SML<\/strong> is an A-IOL that induces accommodation power by forward and backward movements of the lens optic. It also has other advantages such as reducing the risk of formation of secondary cataract. The SML has the potential to replace the conventional IOL which uses more than 30 million pieces annually. The preparation of a product for clinical use has been completed. Its clinical trials will be conducted in India.<\/span><\/p>

In 2020, the development of the A-IOL was halted just as the pre-clinical study was starting in India. This was due to the unexpected occurrence of COVID-19 pandemic. During this period, Mirai Eye Inc. started to develop<\/strong> eight surgical instruments<\/strong> with Meiho Co. Ltd. Among these, three instruments have been developed further to sell globally from Autumn 2021 in succession.\u00a0Our goal is to provide ground-breaking IOLs which enable a better vision to patients affected by cataract and presbyopia. We would also like to contribute to fostering a society in which people can continue to live actively despite ageing.<\/p>

President & CEO<\/strong>
Junsuke Akura<\/strong><\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

\u25a0 Company Profile<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

Company Name<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Mirai Eye Inc.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t

Founding Date<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

25 May 2017<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t

Head Office<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

201 Haitsu Aoba, 3-9-8 Koshienguchi, Nishinomiya, Hyogo, Japan 663-8113<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t

E-mail Address<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

info@miraieye.co.jp<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t

Capital & Capital Reserves<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

53 Million Yen<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t

Contact Number<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

+81 (0)90-3162-7021<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

Major Businesses Objectives<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
  • Develop, produce and distribute intraocular lenses (IOLs).<\/li>
  • Develop, manufacture and trade medical devices, pharmaceutical drugs and non-quasi materials.<\/li>
  • Provide medical consultation services.<\/li>
  • Produce publications for the production of medical materials and business development services.<\/li>
  • Conduct relevant symposiums and workshops on intraocular lens (IOL), surgeries and other medical procedures.<\/li>
  • Offer accounting and general business system support to medical institutions, companies and individuals.<\/li><\/ul>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
    \n\t\t\t\t\t\t
    \n\t\t\t\t\t
    \n\t\t\t
    \n\t\t\t\t\t\t\t\t
    \n\t\t\t\t\t\t
    \n\t\t\t\t\t
    \n\t\t\t
    \n\t\t\t\t\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t

    \u25a0 Company History<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\r\n
    \r\n
    <\/div> \r\n
    \r\n
    2008<\/div><\/div>
    <\/div>
    <\/div>
    Dr Junsuke Akura founded Frontier Vision Inc. for the development and distribution of a cataract surgery simulator under the name \u201cKitaro\u201d. Kitaro was marketed across the world via distribution agents in the EU, USA, Korea, India, Singapore, China, and Colombia.<\/div>
    <\/div>\r\n <\/div>\r\n <\/div>
    \r\n
    2010<\/div><\/div>
    <\/div>
    <\/div>
    With the funds raised from IOL development supporters, Dr Akura began the development of an accommodative intraocular lens (A-IOL).<\/div>
    <\/div>\r\n <\/div>\r\n <\/div>
    \r\n
    2012<\/div><\/div>
    <\/div>
    <\/div>
    The prototype of the A-IOL (M-ring) was prepared and subjected to animal studies at the laboratory of Professor Naganobu at Miyazaki University\u2019s Veterinary Hospital. To accelerate the development of the A-IOL, Dr Akura assumed the position of Professor at the Center for Promoting Next-Generation Highly Advanced Medicine at Tottori University Hospital.<\/div>
    <\/div>\r\n <\/div>\r\n <\/div>
    \r\n
    2014<\/div><\/div>
    <\/div>
    <\/div>
    The development of the A-IOL was adopted by the Japan Agency for Medical Research and Development (AMED) as an A-STEP high-risk project. The R&D of the A-IOL was mainly undertaken by Frontier Vision Inc., Tottori University Hospital, Miyazaki University Veterinary Hospital, and Kunimune Inc; with Kimera Inc. and Meiho Co. Ltd. as the supporting companies.<\/div>
    <\/div>\r\n <\/div>\r\n <\/div>
    \r\n
    2016<\/div><\/div>
    <\/div>
    <\/div>
    AMED\u2019s A-STEP Project was completed. In the same month, Dr Akura resigned from Tottori University.<\/div>
    <\/div>\r\n <\/div>\r\n <\/div>
    \r\n
    2017<\/div><\/div>
    <\/div>
    <\/div>
    Mirai Eye Inc. was founded to accelerate the commercialisation of the A-IOL, with Dr Akura serving as a shareholder in addition to serving as President & CEO of the corporation. The company began the development of the Simple-Move Lens (SML) and the Active-Move Lens (AML). Dr Akura, who believed that confirming the product\u2019s safety in animal studies would be important, began to work as a researcher at the Miyazaki University Veterinary Hospital.<\/div>
    <\/div>\r\n <\/div>\r\n <\/div>
    \r\n
    2018<\/div><\/div>
    <\/div>
    <\/div>
    The development of the SML was presented by Dr Akura at the 122nd Annual Meeting of the Japanese Ophthalmological Society.<\/div>
    <\/div>\r\n <\/div>\r\n <\/div>
    \r\n
    2019<\/div><\/div>
    <\/div>
    <\/div>
    The pre-clinical study of the SML was done in India. However, we could not proceed to the clinical stage due to a protocol failure.<\/div>
    <\/div>\r\n <\/div>\r\n <\/div>
    \r\n
    2020<\/div><\/div>
    <\/div>
    <\/div>
    The development of the A-IOL was halted just as the pre-clinical study was starting to use the optimized SML in India. This was due to the sudden beginning of COVID-19 pandemic. During this period we started to develop eight surgical instruments.<\/div>
    <\/div>\r\n <\/div>\r\n <\/div>
    \r\n
    2021<\/div><\/div>
    <\/div>
    <\/div>
    Mirai Eye Inc. received a second-class manufacturing and distribution authorization license for medical devices.<\/div>
    <\/div>\r\n <\/div>\r\n <\/div>
    \r\n
    2022<\/div><\/div>
    <\/div>
    <\/div>
    Among eight, three types of surgical instruments (eyelid speculum, eye drape, and pupil expander) have been developed and are planned to be sold globally soon.<\/div>
    <\/div>\r\n <\/div>\r\n <\/div><\/div>\r\n
    <\/div>\r\n <\/div>